Aerus ActivePure® Technology Announces SARS-CoV-2 Test Results
Aerus, the global leader in air and surface purification solutions, announced today that testing data conducted by independent FDA-compliant laboratory, MRIGlobal, established a 99.98% surface kill rate of live SARS-CoV-2 virus in just 7 hours with the Aerus Hydroxyl Blaster air and surface purifier.
Data collected in the study showed a 93% surface kill in 3 hours and 98% surface kill in 6 hours of live SARS-CoV-2, even when covered by a protective biofilm, with the Aerus Hydroxyl Blaster and its patented ActivePure® Technology.
In addition, Aerus is running independent laboratory tests to demonstrate the efficacy of ActivePure® Technology on airborne SARS-CoV-2 virus. These results will be submitted to the FDA for review and clearance. Aerus Technology has a 99.9999% kill rate of airborne RNA viruses in just 60 minutes and 99.999% in 30 minutes, as proven with the FDA 510(k) cleared Aerus Medical Guardian with ActivePure®, and performs materially faster on airborne pathogens while it simultaneously destroys surface pathogens. The patented, photocatalyst ActivePure® Technology in the Aerus Hydroxyl Blaster is the same ActivePure® Technology used in the Aerus FDA Class II Medical Device, the Aerus Medical Guardian.
Aerus is confident its upcoming SARS-CoV-2 RNA virus airborne tests will demonstrate strong performance both in speed and the reduction level of the SARS-CoV-2 virus in the air, based on the airborne test results with non-lipid surrogate, MS2 Bacteriophage RNA virus. The SARS-CoV-2 RNA virus is a lipid virus, which the FDA has acknowledged is easier to destroy than non-lipid viruses. Aerus is working expeditiously to confirm the airborne disinfection rate on the SARS-CoV-2 virus.
When available, this data will be submitted to the FDA for clearance. Aerus is awaiting final approval from the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for the Aerus Hydroxyl Blaster with ActivePure® Technology for use in reducing SARS-CoV-2 surface pathogens. The results have also been submitted by Aerus to the FDA-equivalent Canadian and European Union regulators, requesting that they clear Aerus ActivePure® devices to combat the SARS-CoV-2 coronavirus. Aerus expects to receive clearances in all jurisdictions in the near future.